| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hearing Loss | 9 | 2026 | 53 | 6.710 |
Why?
|
| Intrinsically Disordered Proteins | 7 | 2022 | 14 | 4.090 |
Why?
|
| Dogs | 30 | 2025 | 315 | 3.800 |
Why?
|
| Disability Evaluation | 6 | 2025 | 216 | 3.340 |
Why?
|
| Biological Evolution | 9 | 2025 | 127 | 3.260 |
Why?
|
| Evolution, Molecular | 20 | 2024 | 348 | 2.860 |
Why?
|
| International Classification of Functioning, Disability and Health | 5 | 2025 | 6 | 2.840 |
Why?
|
| Domestication | 4 | 2025 | 5 | 2.830 |
Why?
|
| Genomics | 21 | 2025 | 383 | 2.760 |
Why?
|
| Activities of Daily Living | 4 | 2025 | 293 | 2.510 |
Why?
|
| Behavior, Animal | 5 | 2025 | 234 | 2.470 |
Why?
|
| Protein Folding | 7 | 2024 | 268 | 2.200 |
Why?
|
| Sweden | 15 | 2026 | 64 | 2.190 |
Why?
|
| Genome | 25 | 2024 | 285 | 2.100 |
Why?
|
| Eutheria | 8 | 2024 | 8 | 1.990 |
Why?
|
| Genome-Wide Association Study | 17 | 2025 | 361 | 1.970 |
Why?
|
| Dog Diseases | 11 | 2025 | 47 | 1.840 |
Why?
|
| Hearing Aids | 5 | 2025 | 9 | 1.770 |
Why?
|
| Deafness | 2 | 2025 | 35 | 1.520 |
Why?
|
| Animals | 76 | 2026 | 21287 | 1.510 |
Why?
|
| Psychometrics | 5 | 2026 | 391 | 1.480 |
Why?
|
| Reproducibility of Results | 13 | 2026 | 1691 | 1.440 |
Why?
|
| Genetic Variation | 17 | 2023 | 393 | 1.420 |
Why?
|
| Genetic Testing | 2 | 2025 | 141 | 1.380 |
Why?
|
| Foxes | 2 | 2020 | 3 | 1.270 |
Why?
|
| Job Satisfaction | 3 | 2024 | 142 | 1.210 |
Why?
|
| Humans | 81 | 2026 | 64935 | 1.140 |
Why?
|
| Obsessive-Compulsive Disorder | 5 | 2025 | 35 | 1.130 |
Why?
|
| Surveys and Questionnaires | 12 | 2026 | 2759 | 1.050 |
Why?
|
| Breast Neoplasms | 8 | 2019 | 1217 | 1.050 |
Why?
|
| Bloodless Medical and Surgical Procedures | 1 | 2026 | 2 | 0.980 |
Why?
|
| Nurses | 2 | 2024 | 107 | 0.980 |
Why?
|
| Mammals | 7 | 2026 | 222 | 0.970 |
Why?
|
| Jehovah's Witnesses | 1 | 2026 | 19 | 0.970 |
Why?
|
| Religion and Medicine | 1 | 2026 | 20 | 0.960 |
Why?
|
| Female | 45 | 2026 | 33917 | 0.960 |
Why?
|
| Blood Loss, Surgical | 1 | 2026 | 65 | 0.960 |
Why?
|
| Treatment Refusal | 1 | 2026 | 58 | 0.960 |
Why?
|
| Postoperative Hemorrhage | 1 | 2026 | 40 | 0.950 |
Why?
|
| Sign Language | 1 | 2025 | 16 | 0.940 |
Why?
|
| Social Support | 2 | 2025 | 391 | 0.930 |
Why?
|
| Hearing | 1 | 2025 | 25 | 0.930 |
Why?
|
| Mobile Health Units | 1 | 2025 | 20 | 0.930 |
Why?
|
| Auditory Perception | 1 | 2025 | 34 | 0.920 |
Why?
|
| Animals, Domestic | 3 | 2020 | 15 | 0.910 |
Why?
|
| Nuclear Receptor Coactivator 3 | 3 | 2020 | 3 | 0.910 |
Why?
|
| CREB-Binding Protein | 3 | 2020 | 15 | 0.900 |
Why?
|
| Blood Transfusion | 1 | 2026 | 164 | 0.890 |
Why?
|
| Selection, Genetic | 8 | 2020 | 90 | 0.880 |
Why?
|
| Genetics, Behavioral | 1 | 2024 | 10 | 0.870 |
Why?
|
| Adult | 22 | 2026 | 17307 | 0.870 |
Why?
|
| Male | 34 | 2026 | 30942 | 0.840 |
Why?
|
| Biodiversity | 4 | 2023 | 49 | 0.840 |
Why?
|
| Phenotype | 12 | 2025 | 1231 | 0.840 |
Why?
|
| Osteosarcoma | 4 | 2025 | 48 | 0.830 |
Why?
|
| Circular Dichroism | 3 | 2024 | 108 | 0.830 |
Why?
|
| Vertebrates | 3 | 2020 | 42 | 0.830 |
Why?
|
| Aged | 13 | 2026 | 14917 | 0.810 |
Why?
|
| Biomarkers, Tumor | 6 | 2018 | 521 | 0.800 |
Why?
|
| Workplace | 4 | 2026 | 179 | 0.800 |
Why?
|
| Genetics | 1 | 2023 | 14 | 0.800 |
Why?
|
| Central Nervous System Diseases | 1 | 2023 | 57 | 0.770 |
Why?
|
| Patient Care Team | 1 | 2025 | 335 | 0.760 |
Why?
|
| Bone Neoplasms | 3 | 2025 | 121 | 0.760 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2026 | 268 | 0.740 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 2 | 2019 | 3 | 0.730 |
Why?
|
| Phylogeny | 13 | 2024 | 386 | 0.730 |
Why?
|
| Middle Aged | 18 | 2026 | 18203 | 0.730 |
Why?
|
| Cross-Sectional Studies | 8 | 2025 | 2701 | 0.720 |
Why?
|
| Aged, 80 and over | 7 | 2026 | 5600 | 0.700 |
Why?
|
| Audiology | 3 | 2026 | 5 | 0.700 |
Why?
|
| Protein Binding | 9 | 2022 | 1639 | 0.690 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2021 | 49 | 0.690 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 3 | 2015 | 21 | 0.680 |
Why?
|
| Atrial Fibrillation | 3 | 2024 | 871 | 0.660 |
Why?
|
| Genome, Human | 8 | 2023 | 237 | 0.650 |
Why?
|
| Zebrafish | 2 | 2023 | 369 | 0.650 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2020 | 2 | 0.650 |
Why?
|
| Cholera | 3 | 2018 | 16 | 0.650 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2020 | 12 | 0.640 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2015 | 132 | 0.620 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2018 | 215 | 0.610 |
Why?
|
| Protein Domains | 4 | 2021 | 153 | 0.610 |
Why?
|
| Gene Expression Profiling | 6 | 2026 | 793 | 0.600 |
Why?
|
| Polymorphism, Single Nucleotide | 14 | 2025 | 509 | 0.590 |
Why?
|
| Genetic Loci | 5 | 2025 | 116 | 0.580 |
Why?
|
| Epigenomics | 1 | 2019 | 62 | 0.580 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 2 | 2019 | 12 | 0.570 |
Why?
|
| Pets | 1 | 2018 | 6 | 0.570 |
Why?
|
| Sequence Analysis, DNA | 3 | 2019 | 414 | 0.560 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 3 | 2019 | 103 | 0.560 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2019 | 53 | 0.560 |
Why?
|
| Uncertainty | 1 | 2018 | 39 | 0.560 |
Why?
|
| Chromatin | 4 | 2024 | 641 | 0.530 |
Why?
|
| Chromosome Mapping | 8 | 2015 | 295 | 0.530 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 217 | 0.510 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2025 | 730 | 0.510 |
Why?
|
| Health Personnel | 3 | 2026 | 384 | 0.500 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 918 | 0.500 |
Why?
|
| Primary Health Care | 5 | 2025 | 721 | 0.490 |
Why?
|
| Kinetics | 4 | 2022 | 759 | 0.480 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2015 | 7 | 0.480 |
Why?
|
| Protein Conformation | 4 | 2021 | 791 | 0.460 |
Why?
|
| Workload | 3 | 2024 | 130 | 0.460 |
Why?
|
| Young Adult | 5 | 2026 | 4793 | 0.460 |
Why?
|
| Translations | 2 | 2025 | 8 | 0.450 |
Why?
|
| Nerve Tissue Proteins | 3 | 2017 | 428 | 0.440 |
Why?
|
| Translating | 2 | 2025 | 21 | 0.440 |
Why?
|
| DNA Copy Number Variations | 4 | 2024 | 72 | 0.440 |
Why?
|
| Personnel Turnover | 2 | 2024 | 24 | 0.430 |
Why?
|
| Hemangiosarcoma | 3 | 2021 | 24 | 0.430 |
Why?
|
| Desmocollins | 1 | 2014 | 2 | 0.420 |
Why?
|
| Carboxypeptidases | 1 | 2014 | 9 | 0.420 |
Why?
|
| Catenins | 1 | 2014 | 14 | 0.420 |
Why?
|
| DNA Transposable Elements | 4 | 2023 | 159 | 0.420 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2014 | 23 | 0.420 |
Why?
|
| Leadership | 3 | 2024 | 211 | 0.410 |
Why?
|
| Amino Acid Sequence | 6 | 2024 | 1589 | 0.400 |
Why?
|
| Breeding | 5 | 2022 | 29 | 0.390 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2024 | 119 | 0.380 |
Why?
|
| Molecular Sequence Annotation | 3 | 2023 | 66 | 0.380 |
Why?
|
| Registries | 4 | 2024 | 909 | 0.380 |
Why?
|
| Models, Molecular | 5 | 2021 | 1161 | 0.380 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 2 | 2014 | 13 | 0.370 |
Why?
|
| Protein Conformation, alpha-Helical | 3 | 2024 | 22 | 0.370 |
Why?
|
| Protein Interaction Domains and Motifs | 3 | 2022 | 86 | 0.360 |
Why?
|
| Eukaryota | 2 | 2022 | 31 | 0.350 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2011 | 11 | 0.350 |
Why?
|
| Tamoxifen | 3 | 2018 | 42 | 0.350 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2011 | 33 | 0.350 |
Why?
|
| Gene Dosage | 5 | 2019 | 71 | 0.340 |
Why?
|
| Rodentia | 2 | 2021 | 20 | 0.330 |
Why?
|
| Molecular Dynamics Simulation | 2 | 2022 | 134 | 0.330 |
Why?
|
| Base Sequence | 4 | 2022 | 1329 | 0.320 |
Why?
|
| Farms | 2 | 2020 | 4 | 0.320 |
Why?
|
| Sequence Alignment | 2 | 2020 | 300 | 0.310 |
Why?
|
| Signal Transduction | 9 | 2019 | 3141 | 0.310 |
Why?
|
| Haplotypes | 10 | 2020 | 134 | 0.310 |
Why?
|
| Mutation | 7 | 2023 | 2657 | 0.300 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 790 | 0.300 |
Why?
|
| Hair Color | 2 | 2014 | 7 | 0.300 |
Why?
|
| Risk Factors | 6 | 2026 | 5406 | 0.290 |
Why?
|
| Brain | 4 | 2023 | 1600 | 0.290 |
Why?
|
| Gene Expression | 2 | 2011 | 852 | 0.290 |
Why?
|
| Sick Leave | 2 | 2025 | 23 | 0.280 |
Why?
|
| Retrospective Studies | 5 | 2026 | 6840 | 0.270 |
Why?
|
| Genetic Linkage | 1 | 2007 | 97 | 0.260 |
Why?
|
| Conserved Sequence | 4 | 2023 | 173 | 0.260 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2018 | 38 | 0.260 |
Why?
|
| Software | 3 | 2020 | 394 | 0.260 |
Why?
|
| Thermodynamics | 3 | 2024 | 196 | 0.260 |
Why?
|
| Liquid-Liquid Extraction | 1 | 2026 | 3 | 0.250 |
Why?
|
| Fibroins | 1 | 2026 | 6 | 0.250 |
Why?
|
| Silk | 1 | 2026 | 8 | 0.250 |
Why?
|
| Chiroptera | 2 | 2024 | 17 | 0.240 |
Why?
|
| Immunity, Mucosal | 2 | 2018 | 53 | 0.240 |
Why?
|
| Models, Animal | 3 | 2023 | 241 | 0.240 |
Why?
|
| Amyloid | 1 | 2026 | 73 | 0.230 |
Why?
|
| Work Capacity Evaluation | 1 | 2025 | 19 | 0.230 |
Why?
|
| Extinction, Biological | 2 | 2023 | 8 | 0.230 |
Why?
|
| Vibrio cholerae | 2 | 2018 | 18 | 0.230 |
Why?
|
| Species Specificity | 7 | 2026 | 339 | 0.230 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 312 | 0.230 |
Why?
|
| Neoplasms | 4 | 2025 | 1364 | 0.230 |
Why?
|
| Comprehension | 2 | 2023 | 138 | 0.230 |
Why?
|
| Proteins | 2 | 2024 | 764 | 0.230 |
Why?
|
| Factor Analysis, Statistical | 1 | 2025 | 100 | 0.230 |
Why?
|
| Epigenesis, Genetic | 2 | 2026 | 406 | 0.230 |
Why?
|
| Homeostasis | 2 | 2026 | 377 | 0.230 |
Why?
|
| Correction of Hearing Impairment | 1 | 2025 | 3 | 0.220 |
Why?
|
| South Africa | 1 | 2025 | 15 | 0.220 |
Why?
|
| Mouth Neoplasms | 1 | 2025 | 41 | 0.220 |
Why?
|
| Physicians, Primary Care | 1 | 2025 | 78 | 0.220 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2024 | 277 | 0.220 |
Why?
|
| Synteny | 3 | 2022 | 24 | 0.220 |
Why?
|
| Regulatory Elements, Transcriptional | 2 | 2023 | 38 | 0.220 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2015 | 211 | 0.220 |
Why?
|
| India | 1 | 2025 | 164 | 0.210 |
Why?
|
| Machine Learning | 2 | 2024 | 192 | 0.210 |
Why?
|
| Vocalization, Animal | 1 | 2024 | 4 | 0.210 |
Why?
|
| Lactobacillaceae | 1 | 2024 | 2 | 0.210 |
Why?
|
| Lassa Fever | 1 | 2024 | 5 | 0.210 |
Why?
|
| Gene Duplication | 4 | 2019 | 32 | 0.210 |
Why?
|
| Intention | 1 | 2024 | 73 | 0.210 |
Why?
|
| Social Security | 1 | 2023 | 9 | 0.210 |
Why?
|
| Predictive Value of Tests | 2 | 2025 | 1103 | 0.210 |
Why?
|
| Gene Expression Regulation | 6 | 2024 | 1629 | 0.210 |
Why?
|
| Burnout, Professional | 1 | 2026 | 142 | 0.200 |
Why?
|
| Time Factors | 3 | 2026 | 3753 | 0.200 |
Why?
|
| Pandemics | 3 | 2024 | 672 | 0.200 |
Why?
|
| Precision Medicine | 1 | 2025 | 128 | 0.200 |
Why?
|
| Motor Cortex | 1 | 2024 | 72 | 0.200 |
Why?
|
| Focus Groups | 1 | 2025 | 319 | 0.200 |
Why?
|
| Self Report | 1 | 2026 | 391 | 0.200 |
Why?
|
| Vascular Diseases | 1 | 2024 | 81 | 0.200 |
Why?
|
| Cerebellar Neoplasms | 1 | 2023 | 10 | 0.200 |
Why?
|
| Medulloblastoma | 1 | 2023 | 13 | 0.200 |
Why?
|
| Ligands | 2 | 2022 | 415 | 0.200 |
Why?
|
| Delphi Technique | 1 | 2023 | 111 | 0.200 |
Why?
|
| Longevity | 2 | 2024 | 117 | 0.200 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2019 | 439 | 0.200 |
Why?
|
| Disease | 1 | 2023 | 26 | 0.190 |
Why?
|
| Body Size | 2 | 2021 | 19 | 0.190 |
Why?
|
| Recombinant Proteins | 2 | 2026 | 710 | 0.190 |
Why?
|
| Sequence Deletion | 1 | 2023 | 115 | 0.190 |
Why?
|
| Karyotype | 1 | 2022 | 18 | 0.190 |
Why?
|
| Motor Neurons | 1 | 2024 | 218 | 0.190 |
Why?
|
| Neurogenesis | 1 | 2023 | 64 | 0.190 |
Why?
|
| Seals, Earless | 1 | 2022 | 1 | 0.180 |
Why?
|
| Physicians | 2 | 2024 | 473 | 0.180 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 159 | 0.180 |
Why?
|
| Risk Assessment | 2 | 2026 | 2093 | 0.180 |
Why?
|
| Panthera | 1 | 2021 | 2 | 0.180 |
Why?
|
| Quality of Health Care | 1 | 2026 | 526 | 0.180 |
Why?
|
| Emergencies | 1 | 2021 | 122 | 0.170 |
Why?
|
| Ambulatory Care Facilities | 1 | 2021 | 105 | 0.170 |
Why?
|
| Vascular Neoplasms | 1 | 2021 | 18 | 0.170 |
Why?
|
| Genotype | 6 | 2024 | 673 | 0.170 |
Why?
|
| Quantitative Trait Loci | 4 | 2015 | 81 | 0.170 |
Why?
|
| Cell Membrane | 1 | 2023 | 505 | 0.170 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2023 | 663 | 0.160 |
Why?
|
| Mole Rats | 1 | 2020 | 1 | 0.160 |
Why?
|
| Education | 1 | 2021 | 66 | 0.160 |
Why?
|
| Organ Size | 1 | 2020 | 173 | 0.160 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 45 | 0.160 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2020 | 251 | 0.160 |
Why?
|
| Static Electricity | 1 | 2020 | 170 | 0.160 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2011 | 297 | 0.160 |
Why?
|
| Cat Diseases | 2 | 2018 | 19 | 0.160 |
Why?
|
| Cats | 2 | 2018 | 89 | 0.160 |
Why?
|
| Patient Satisfaction | 1 | 2023 | 434 | 0.160 |
Why?
|
| Otters | 1 | 2019 | 1 | 0.160 |
Why?
|
| Shrews | 1 | 2019 | 2 | 0.160 |
Why?
|
| Venoms | 1 | 2019 | 11 | 0.160 |
Why?
|
| Disks Large Homolog 4 Protein | 1 | 2019 | 21 | 0.160 |
Why?
|
| Qualitative Research | 1 | 2024 | 745 | 0.150 |
Why?
|
| Adaptation, Biological | 1 | 2019 | 19 | 0.150 |
Why?
|
| Severity of Illness Index | 1 | 2025 | 1557 | 0.150 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2020 | 281 | 0.150 |
Why?
|
| Caniformia | 1 | 2019 | 1 | 0.150 |
Why?
|
| Guanylate Cyclase | 1 | 2019 | 11 | 0.150 |
Why?
|
| Renal Circulation | 1 | 2019 | 14 | 0.150 |
Why?
|
| Vasoconstriction | 1 | 2019 | 22 | 0.150 |
Why?
|
| Protein Structure, Tertiary | 1 | 2020 | 676 | 0.150 |
Why?
|
| Diving | 1 | 2019 | 8 | 0.150 |
Why?
|
| Calcium-Binding Proteins | 2 | 2017 | 94 | 0.150 |
Why?
|
| Duodenum | 2 | 2018 | 41 | 0.140 |
Why?
|
| Legislation, Veterinary | 1 | 2018 | 1 | 0.140 |
Why?
|
| Veterinary Medicine | 1 | 2018 | 3 | 0.140 |
Why?
|
| Genetic Counseling | 1 | 2018 | 16 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 2 | 2014 | 687 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 181 | 0.140 |
Why?
|
| Mammoths | 1 | 2018 | 1 | 0.140 |
Why?
|
| Mastodons | 1 | 2018 | 1 | 0.140 |
Why?
|
| Bacterial Proteins | 1 | 2024 | 739 | 0.140 |
Why?
|
| Elephants | 1 | 2018 | 6 | 0.140 |
Why?
|
| Treatment Outcome | 3 | 2026 | 5775 | 0.140 |
Why?
|
| Conflict of Interest | 1 | 2018 | 38 | 0.140 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 180 | 0.140 |
Why?
|
| Quantitative Trait, Heritable | 2 | 2015 | 28 | 0.140 |
Why?
|
| Patient Discharge | 1 | 2021 | 518 | 0.130 |
Why?
|
| Fever | 2 | 2024 | 64 | 0.130 |
Why?
|
| Cerebrovascular Circulation | 1 | 2019 | 183 | 0.130 |
Why?
|
| Crystallography, X-Ray | 1 | 2018 | 419 | 0.130 |
Why?
|
| Demography | 2 | 2021 | 178 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 542 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 205 | 0.130 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 158 | 0.130 |
Why?
|
| Mice | 8 | 2023 | 11086 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 219 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 318 | 0.130 |
Why?
|
| MicroRNAs | 2 | 2013 | 710 | 0.130 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 1161 | 0.130 |
Why?
|
| Transcription Factors | 2 | 2023 | 1551 | 0.130 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2007 | 100 | 0.120 |
Why?
|
| Kidney | 1 | 2019 | 450 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2016 | 7 | 0.120 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2016 | 17 | 0.120 |
Why?
|
| Chromosomes, Mammalian | 3 | 2022 | 33 | 0.120 |
Why?
|
| Polymorphism, Genetic | 2 | 2014 | 198 | 0.120 |
Why?
|
| Gene Amplification | 2 | 2016 | 27 | 0.120 |
Why?
|
| Eccrine Glands | 1 | 2015 | 3 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 426 | 0.110 |
Why?
|
| Vibrio cholerae O1 | 1 | 2015 | 6 | 0.110 |
Why?
|
| Hair Follicle | 1 | 2015 | 36 | 0.110 |
Why?
|
| Convalescence | 1 | 2015 | 17 | 0.110 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2015 | 44 | 0.110 |
Why?
|
| Prognosis | 3 | 2019 | 1775 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 800 | 0.110 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2015 | 156 | 0.110 |
Why?
|
| Lymphoma, B-Cell | 1 | 2015 | 63 | 0.110 |
Why?
|
| Microsatellite Repeats | 1 | 2014 | 42 | 0.110 |
Why?
|
| NF-kappa B | 2 | 2013 | 434 | 0.110 |
Why?
|
| Stroke | 1 | 2023 | 1208 | 0.110 |
Why?
|
| Binding Sites | 3 | 2023 | 920 | 0.110 |
Why?
|
| Ataxin-1 | 1 | 2014 | 4 | 0.110 |
Why?
|
| Animals, Inbred Strains | 1 | 2014 | 3 | 0.110 |
Why?
|
| Ataxins | 1 | 2014 | 5 | 0.110 |
Why?
|
| Immunohistochemistry | 4 | 2019 | 895 | 0.100 |
Why?
|
| Case-Control Studies | 3 | 2025 | 1138 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 372 | 0.100 |
Why?
|
| Disease Models, Animal | 2 | 2025 | 2282 | 0.100 |
Why?
|
| Survival Analysis | 2 | 2013 | 576 | 0.100 |
Why?
|
| Ectoderm | 2 | 2015 | 12 | 0.100 |
Why?
|
| Carcinogenesis | 1 | 2015 | 134 | 0.100 |
Why?
|
| Survival Rate | 1 | 2015 | 843 | 0.100 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2013 | 84 | 0.100 |
Why?
|
| Rivers | 1 | 2013 | 23 | 0.100 |
Why?
|
| Adolescent | 1 | 2024 | 6292 | 0.100 |
Why?
|
| Inflammasomes | 2 | 2015 | 348 | 0.100 |
Why?
|
| Genetic Techniques | 1 | 2013 | 39 | 0.100 |
Why?
|
| Whole Genome Sequencing | 2 | 2025 | 85 | 0.090 |
Why?
|
| Immunity, Innate | 1 | 2018 | 819 | 0.090 |
Why?
|
| Epilepsies, Partial | 1 | 2011 | 18 | 0.090 |
Why?
|
| United States | 1 | 2025 | 8082 | 0.090 |
Why?
|
| Glucuronosyltransferase | 1 | 2011 | 9 | 0.090 |
Why?
|
| Fossils | 2 | 2023 | 7 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 309 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 583 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 286 | 0.080 |
Why?
|
| Chromosomes, Artificial, Bacterial | 2 | 2007 | 19 | 0.080 |
Why?
|
| Attitude of Health Personnel | 2 | 2025 | 625 | 0.080 |
Why?
|
| Phosphoproteins | 1 | 2011 | 224 | 0.080 |
Why?
|
| Drug Resistance | 1 | 2011 | 154 | 0.080 |
Why?
|
| Antimalarials | 1 | 2011 | 125 | 0.080 |
Why?
|
| Phytophthora infestans | 1 | 2009 | 1 | 0.080 |
Why?
|
| Prevalence | 2 | 2024 | 1439 | 0.080 |
Why?
|
| Wolves | 2 | 2023 | 3 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2015 | 918 | 0.080 |
Why?
|
| Plant Diseases | 1 | 2009 | 11 | 0.080 |
Why?
|
| RNA, Messenger | 1 | 2015 | 1576 | 0.080 |
Why?
|
| Sarcoma | 1 | 2009 | 36 | 0.080 |
Why?
|
| Solanum tuberosum | 1 | 2009 | 13 | 0.080 |
Why?
|
| Receptors, Estrogen | 2 | 2012 | 129 | 0.070 |
Why?
|
| Ectodermal Dysplasia | 1 | 2008 | 6 | 0.070 |
Why?
|
| Homeodomain Proteins | 2 | 2013 | 277 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 402 | 0.070 |
Why?
|
| Frameshift Mutation | 1 | 2008 | 29 | 0.070 |
Why?
|
| Plasmodium falciparum | 1 | 2011 | 255 | 0.070 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2010 | 183 | 0.070 |
Why?
|
| Forkhead Transcription Factors | 1 | 2008 | 132 | 0.070 |
Why?
|
| Dermoid Cyst | 1 | 2007 | 3 | 0.070 |
Why?
|
| Spina Bifida Occulta | 1 | 2007 | 3 | 0.070 |
Why?
|
| Skin Abnormalities | 1 | 2007 | 8 | 0.070 |
Why?
|
| Skin | 1 | 2011 | 419 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2008 | 266 | 0.070 |
Why?
|
| Fibroblast Growth Factors | 1 | 2007 | 77 | 0.060 |
Why?
|
| Melanocytes | 1 | 2007 | 77 | 0.060 |
Why?
|
| Spiders | 1 | 2026 | 17 | 0.060 |
Why?
|
| Aging | 2 | 2024 | 763 | 0.060 |
Why?
|
| Genomic Library | 1 | 2005 | 10 | 0.060 |
Why?
|
| Pregnancy | 2 | 2023 | 2372 | 0.060 |
Why?
|
| Urochordata | 1 | 2005 | 1 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2019 | 1564 | 0.060 |
Why?
|
| Proteomics | 2 | 2019 | 292 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2005 | 10 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2005 | 30 | 0.060 |
Why?
|
| Norway | 1 | 2024 | 23 | 0.050 |
Why?
|
| Biopsy | 2 | 2018 | 454 | 0.050 |
Why?
|
| Finland | 1 | 2024 | 19 | 0.050 |
Why?
|
| Transcriptome | 2 | 2020 | 398 | 0.050 |
Why?
|
| Multigene Family | 2 | 2021 | 106 | 0.050 |
Why?
|
| Larynx | 1 | 2024 | 15 | 0.050 |
Why?
|
| Human Genetics | 1 | 2024 | 2 | 0.050 |
Why?
|
| Lassa virus | 1 | 2024 | 5 | 0.050 |
Why?
|
| Response Elements | 1 | 2004 | 44 | 0.050 |
Why?
|
| Literacy | 1 | 2023 | 6 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2024 | 51 | 0.050 |
Why?
|
| Fatigue | 1 | 2024 | 113 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2025 | 179 | 0.050 |
Why?
|
| Birds | 1 | 2023 | 10 | 0.050 |
Why?
|
| Population Density | 1 | 2023 | 13 | 0.050 |
Why?
|
| Protein Phosphatase 2 | 1 | 2023 | 11 | 0.050 |
Why?
|
| Pan troglodytes | 1 | 2023 | 33 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2023 | 29 | 0.050 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2023 | 14 | 0.050 |
Why?
|
| src-Family Kinases | 1 | 2023 | 64 | 0.050 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2023 | 18 | 0.050 |
Why?
|
| Postmenopause | 2 | 2016 | 238 | 0.050 |
Why?
|
| Primates | 1 | 2023 | 52 | 0.050 |
Why?
|
| Physical Chromosome Mapping | 1 | 2002 | 5 | 0.050 |
Why?
|
| Health Literacy | 1 | 2023 | 87 | 0.050 |
Why?
|
| Sloths | 1 | 2022 | 1 | 0.050 |
Why?
|
| Occupational Health | 1 | 2024 | 193 | 0.050 |
Why?
|
| Histone Deacetylases | 1 | 2023 | 66 | 0.050 |
Why?
|
| Risk | 1 | 2023 | 374 | 0.050 |
Why?
|
| Antarctic Regions | 1 | 2022 | 3 | 0.050 |
Why?
|
| Pedigree | 2 | 2015 | 193 | 0.050 |
Why?
|
| Ecology | 1 | 2022 | 14 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2024 | 529 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2016 | 960 | 0.040 |
Why?
|
| Cattle | 1 | 2022 | 320 | 0.040 |
Why?
|
| Heart | 1 | 2024 | 297 | 0.040 |
Why?
|
| Histones | 1 | 2005 | 494 | 0.040 |
Why?
|
| Growth | 1 | 2021 | 23 | 0.040 |
Why?
|
| Ecosystem | 1 | 2022 | 58 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2021 | 7 | 0.040 |
Why?
|
| Conservation of Natural Resources | 1 | 2021 | 44 | 0.040 |
Why?
|
| Feeding Behavior | 1 | 2023 | 263 | 0.040 |
Why?
|
| Amnion | 1 | 2020 | 9 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1279 | 0.040 |
Why?
|
| Host Specificity | 1 | 2020 | 11 | 0.040 |
Why?
|
| Quality Control | 1 | 2020 | 78 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2026 | 2482 | 0.040 |
Why?
|
| Incidence | 1 | 2024 | 1415 | 0.040 |
Why?
|
| Narration | 1 | 2021 | 53 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2009 | 1979 | 0.040 |
Why?
|
| Comorbidity | 1 | 2023 | 1113 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2004 | 630 | 0.040 |
Why?
|
| Age Factors | 1 | 2024 | 1580 | 0.040 |
Why?
|
| Receptors, Virus | 1 | 2020 | 73 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2017 | 2612 | 0.040 |
Why?
|
| Oxygen | 1 | 2022 | 319 | 0.040 |
Why?
|
| PDZ Domains | 1 | 2019 | 2 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2022 | 225 | 0.040 |
Why?
|
| Guanylate Kinases | 1 | 2019 | 8 | 0.040 |
Why?
|
| Tissue Kallikreins | 1 | 2019 | 2 | 0.040 |
Why?
|
| src Homology Domains | 1 | 2019 | 21 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 2 | 2015 | 278 | 0.040 |
Why?
|
| DNA, Intergenic | 2 | 2010 | 24 | 0.040 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2019 | 2 | 0.040 |
Why?
|
| Algorithms | 1 | 2005 | 1039 | 0.040 |
Why?
|
| Viscera | 1 | 2019 | 10 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 9 | 0.040 |
Why?
|
| Scandinavian and Nordic Countries | 1 | 2019 | 5 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 2019 | 115 | 0.040 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 114 | 0.040 |
Why?
|
| Amino Acids | 1 | 2020 | 148 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2023 | 447 | 0.040 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2019 | 6 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2023 | 522 | 0.040 |
Why?
|
| Blood Vessels | 1 | 2019 | 63 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2019 | 28 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2019 | 65 | 0.040 |
Why?
|
| Second Messenger Systems | 1 | 2019 | 27 | 0.040 |
Why?
|
| Cyclic GMP | 1 | 2019 | 33 | 0.040 |
Why?
|
| Sequence Homology | 1 | 2018 | 21 | 0.040 |
Why?
|
| Students | 1 | 2021 | 225 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 242 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2026 | 3305 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2019 | 129 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 203 | 0.040 |
Why?
|
| Cell Communication | 1 | 2019 | 133 | 0.040 |
Why?
|
| Social Media | 1 | 2021 | 128 | 0.040 |
Why?
|
| Heterozygote | 2 | 2011 | 173 | 0.030 |
Why?
|
| Gene Flow | 1 | 2018 | 7 | 0.030 |
Why?
|
| History, Ancient | 1 | 2018 | 11 | 0.030 |
Why?
|
| Cell Line | 1 | 2022 | 2020 | 0.030 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2019 | 70 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2020 | 483 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2019 | 164 | 0.030 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2017 | 13 | 0.030 |
Why?
|
| Breast | 1 | 2019 | 190 | 0.030 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2017 | 24 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 1224 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 2017 | 135 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 907 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 58 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2007 | 161 | 0.030 |
Why?
|
| Premenopause | 1 | 2016 | 60 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 91 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2015 | 3468 | 0.030 |
Why?
|
| Mastectomy | 1 | 2016 | 56 | 0.030 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2015 | 6 | 0.030 |
Why?
|
| Muscular Dystrophy, Animal | 1 | 2015 | 5 | 0.030 |
Why?
|
| Jagged-1 Protein | 1 | 2015 | 8 | 0.030 |
Why?
|
| Penetrance | 1 | 2015 | 11 | 0.030 |
Why?
|
| Synapses | 1 | 2017 | 193 | 0.030 |
Why?
|
| Dystrophin | 1 | 2015 | 30 | 0.030 |
Why?
|
| Crosses, Genetic | 1 | 2015 | 116 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2015 | 26 | 0.030 |
Why?
|
| Tryptophan-tRNA Ligase | 1 | 2015 | 3 | 0.030 |
Why?
|
| Calgranulin A | 1 | 2015 | 5 | 0.030 |
Why?
|
| Rats | 2 | 2011 | 1989 | 0.030 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2015 | 18 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2015 | 130 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 47 | 0.030 |
Why?
|
| Cloning, Molecular | 2 | 2005 | 384 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 294 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2014 | 122 | 0.030 |
Why?
|
| Zebrafish Proteins | 1 | 2015 | 168 | 0.030 |
Why?
|
| Canada | 1 | 2014 | 153 | 0.030 |
Why?
|
| Laser Capture Microdissection | 1 | 2013 | 2 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 2014 | 94 | 0.030 |
Why?
|
| Europe | 1 | 2014 | 199 | 0.030 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2013 | 8 | 0.030 |
Why?
|
| Mutagenesis | 2 | 2005 | 132 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 197 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2013 | 213 | 0.020 |
Why?
|
| Cadherins | 1 | 2013 | 90 | 0.020 |
Why?
|
| Transfection | 1 | 2015 | 701 | 0.020 |
Why?
|
| HapMap Project | 1 | 2013 | 5 | 0.020 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2013 | 11 | 0.020 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2015 | 350 | 0.020 |
Why?
|
| Flagellin | 1 | 2013 | 14 | 0.020 |
Why?
|
| Acute Disease | 1 | 2015 | 663 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2017 | 718 | 0.020 |
Why?
|
| Alleles | 1 | 2014 | 453 | 0.020 |
Why?
|
| Archaeology | 1 | 2012 | 1 | 0.020 |
Why?
|
| Serine | 1 | 2012 | 90 | 0.020 |
Why?
|
| Phylogeography | 1 | 2012 | 6 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 563 | 0.020 |
Why?
|
| Ear | 1 | 2011 | 9 | 0.020 |
Why?
|
| Genotyping Techniques | 1 | 2011 | 21 | 0.020 |
Why?
|
| Homozygote | 1 | 2011 | 122 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 261 | 0.020 |
Why?
|
| Mefloquine | 1 | 2011 | 4 | 0.020 |
Why?
|
| Phenanthrenes | 1 | 2011 | 6 | 0.020 |
Why?
|
| Fluorenes | 1 | 2011 | 13 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 1036 | 0.020 |
Why?
|
| Ethanolamines | 1 | 2011 | 18 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 47 | 0.020 |
Why?
|
| COS Cells | 1 | 2011 | 180 | 0.020 |
Why?
|
| ADAM Proteins | 1 | 2011 | 36 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 642 | 0.020 |
Why?
|
| Syndrome | 1 | 2011 | 178 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 120 | 0.020 |
Why?
|
| Hyaluronic Acid | 1 | 2011 | 70 | 0.020 |
Why?
|
| Arteritis | 1 | 2010 | 4 | 0.020 |
Why?
|
| Collagen Diseases | 1 | 2010 | 4 | 0.020 |
Why?
|
| Population Groups | 1 | 2010 | 13 | 0.020 |
Why?
|
| Meningitis | 1 | 2010 | 18 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2009 | 26 | 0.020 |
Why?
|
| Antibodies, Antinuclear | 1 | 2010 | 40 | 0.020 |
Why?
|
| Ireland | 1 | 2009 | 17 | 0.020 |
Why?
|
| Starvation | 1 | 2009 | 11 | 0.020 |
Why?
|
| Algal Proteins | 1 | 2009 | 14 | 0.020 |
Why?
|
| Injections | 1 | 2009 | 84 | 0.020 |
Why?
|
| Bacteria | 1 | 2013 | 336 | 0.020 |
Why?
|
| Rheumatic Diseases | 1 | 2010 | 42 | 0.020 |
Why?
|
| Apoptosis | 1 | 2015 | 1100 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 615 | 0.020 |
Why?
|
| Necrosis | 1 | 2009 | 148 | 0.020 |
Why?
|
| Tooth | 1 | 2008 | 4 | 0.020 |
Why?
|
| Ectodysplasins | 1 | 2008 | 2 | 0.020 |
Why?
|
| Vibrissae | 1 | 2008 | 7 | 0.020 |
Why?
|
| Malaria, Falciparum | 1 | 2011 | 233 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2008 | 105 | 0.020 |
Why?
|
| Fibroblast Growth Factor 3 | 1 | 2007 | 2 | 0.020 |
Why?
|
| Hair | 1 | 2008 | 81 | 0.020 |
Why?
|
| Fibroblast Growth Factor 4 | 1 | 2007 | 7 | 0.020 |
Why?
|
| Computational Biology | 1 | 2010 | 367 | 0.020 |
Why?
|
| Short Interspersed Nucleotide Elements | 1 | 2005 | 4 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2007 | 285 | 0.010 |
Why?
|
| Hybridization, Genetic | 1 | 2005 | 30 | 0.010 |
Why?
|
| Diploidy | 1 | 2005 | 11 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 2005 | 28 | 0.010 |
Why?
|
| Neurons | 1 | 2011 | 933 | 0.010 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2005 | 8 | 0.010 |
Why?
|
| Acetylation | 1 | 2005 | 121 | 0.010 |
Why?
|
| Lysine | 1 | 2005 | 94 | 0.010 |
Why?
|
| Methylation | 1 | 2005 | 130 | 0.010 |
Why?
|
| Models, Biological | 1 | 2010 | 1192 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 513 | 0.010 |
Why?
|
| Estrogens | 1 | 2004 | 115 | 0.010 |
Why?
|
| Pseudogenes | 1 | 2002 | 12 | 0.010 |
Why?
|
| Base Composition | 1 | 2002 | 30 | 0.010 |
Why?
|
| Sex Chromosomes | 1 | 2002 | 12 | 0.010 |
Why?
|
| Genes | 1 | 2002 | 90 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2002 | 85 | 0.010 |
Why?
|
| RNA, Untranslated | 1 | 2002 | 105 | 0.010 |
Why?
|
| Proteome | 1 | 2002 | 151 | 0.010 |
Why?
|
| CpG Islands | 1 | 2002 | 219 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2002 | 1287 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2002 | 2152 | 0.010 |
Why?
|